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Abstract
A nanodrug delivery system of paclitaxel-mesoporous silica nanoparticles with a core-shell structure (PAC-csMSN)
was used to increase the dissolution of paclitaxel (PAC) and improve its treatment of lung cancer. PAC was loaded
into the core-shell mesoporous silica nanoparticles (csMSN) by the adsorption equilibrium method and was in an
amorphous state in terms of its mesoporous structure. In vitro and in vivo studies showed that csMSN increased
the dissolution rate of PAC and improved its lung absorption. The area under concentration-time curve (AUC) value
of PAC-csMSN used for pulmonary delivery in rabbits was 2.678-fold higher than that obtained with the PAC. After
continuous administration for 3 days, a lung biopsy showed no signs of inflammation. Cell apoptosis results obtained by
flow cytometry indicated that PAC-csMSN was more potent than pure PAC in promoting cell apoptosis. An absorption
investigation of PAC-csMSN in A549 cells was carried out by transmission electron microscopy (TEM) and laser scanning
confocal microscopy (LSCM). The obtained results indicated that the cellular uptake was time-dependent and csMSN was
uptaken into the cytoplasm. All these results demonstrate that csMSN have the potential to achieve pulmonary inhalation
administration of poorly water-soluble drugs for the treatment of lung cancer.
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Background
Most anticancer drugs are water-insoluble, and the poor
solubility seriously restricts their absorption. Classical
treatment for lung cancer involves oral or intravenous
administration of antifungal drug formulations [1–3].
However, these compounds have many side effects and
are not very effective [4]. For these common routes of
administration, a stable and efficient lung drug concen-
tration is not always guaranteed due to low solubility
and/or poor tissue penetration, which may also lead to a
poor survival prognosis. Pulmonary delivery is an inter-
esting choice because it delivers anticancer drugs
directly to the cancerous tissue while maintaining high
lung drug concentrations and reducing systemic side
effects [5, 6].
PAC, an effective anticancer drug, is poorly water-
soluble (solubility in water is 6 ng/ml). Therefore, how
to improve the solubility of PAC has become an import-
ant challenge. Currently, some methods are available for
improving PAC solubility, such as the use of micelles,
liposomes, and nanoparticles [7–9]. With the develop-
ment of nanotechnology, the application of mesoporous
materials for improving the solubility of poorly water-
soluble drugs is attracting wide attention. Zongzhe zhao
et al. have reported the development of mesoporous
silica materials in improving the solubility of fenofibrate
and regulating its release rate [10]. Peng zhao et al. apply
mesoporous carbon materials to increase the dissolution
rate of poorly water-soluble drugs [11]. Porous hydroxy-
apatite, porous alumina, and porous titanium dioxide
materials have also been used to improve the water solu-
bility of insoluble drugs [12–14].
In our research, we have developed a csMSN-based
PAC nanodrug delivery system for improving the treat-
ment of lung cancer. There are two reasons for choosing
csMSN as carrier for improving PAC solubility. Firstly,
the spatial confinement effect of the mesoporous struc-
ture can reduce the drug particle size and increase the
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specific surface area of the drug particles. According to
the Noyes-Whitney and Ostwald-Freundlich equations,
this would increase the dissolution rate of PAC.
Secondly, csMSN has a regular shape, low density,
and good flowability which make them suitable as a
carrier for pulmonary delivery. In the work, we
wished to investigate whether csMSN could be used
as a pulmonary delivery carrier using a lung absorp-
tion study at a cellular level.
Methods
Materials
PAC was provided by the Dalian Meilun Company with a
purity >99%. Acetonitrile, anhydrous ethanol, butylpara-
ben, Tween 80, tetraethylorthosilicate (TEOS), aminopro-
pyltriethoxysilane (APTES), glutaraldehyde, hypromellose,
hexadecyl trimethyl ammonium bromide (CTAB), ammo-
nia, methyl tert-butyl ether, and dichloromethane were
obtained from the Jin Zhou Xing Bei reagent company.
Fluorescein isothiocyanate (FITC), Hoechst 33342,
rhodamine phalloidin and 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium (MTT) were purchased from
Beijing Dingguo Changsheng Biotechnology Co., Ltd.
Deionized water was used in all experiments.
Synthesis of csMSN
csMSN was prepared according to the process reported
by Wu et al. [15]. Firstly, ethanol, deionized water, and
ammonia (180:65:4.5, v/v/v) were mixed in a glass con-
tainer under stirring. Then, TEOS (15 ml) was slowly
dripped into the solution. The reaction was carried out
for 4 h and then solid silica nanoparticles (SSN) were
obtained by centrifugation at 9500 rpm for 200 min. The
product was then dried at 40 °C. Secondly, ethanol, de-
ionized water, CTAB, and the dried SSN (13:30:150:100,
v/v/m/m) were mixed in a glass container and stirred for
30 min under ultrasonication. Ammonia (0.45 ml) and
TEOS (0.3 ml) were then added to the system and
stirred at room temperature for 6 h. The precipitate ob-
tained by centrifugation was washed repeatedly with
ethanol and water, and then dried at 40 °C. csMSN was
obtained by calcination at 550 °C.
Drug-Loading Procedure
PAC, an anticancer drug, is used clinically to treat ovar-
ian cancer, breast cancer, lung cancer, and colorectal
cancer. It was chosen as a model drug and was loaded
onto csMSN by the adsorption equilibrium method [16].
The drug loading of csMSN was concentration-
dependent. The same amount of csMSN was soaked in
different concentrations of PAC dichloromethane solution
and then the suspension was stirred for 5 h. The super-
natant was removed by centrifugation at 10,000 rpm and,
finally, the drug-loaded sample (PAC-csMSN) was dried
in a vacuum. The drug content was determined by high-
performance liquid chromatography (HPLC) (L-2400,
HITACHI, Japan). The drug loading (DD) of csMSN was
calculated by the formula:
DD ¼ the amount of drug in PAC−csMSN=
the amount of PAC−csMSN:
Characterization of csMSN and PAC-csMSN
The structure and morphology of csMSN was observed
by transmission electron microscopy (TEM; Tecnai
G2F30) and scanning electron microscopy (SEM; JEOL
JSM-7001F). The adsorption analyzer (SA3100, Beckman
Coulter Inc., Brea, CA, USA) was used to detect the spe-
cific surface area and pore size of csMSN. The phase
transition process of PAC in all samples was performed
using differential scanning calorimetry (DSC; Shimadzu
DSC-60, Japan) at a heating rate of 10 °C/min from 25
to 350 °C under a nitrogen flow of 150 ml/min. X-ray
diffraction analysis (XRD; Rigaku Geigerflex XRD, Co.,
Japan,) was used to further investigate the physical state
of PAC in csMSN. The step length was 0.02° and the
scanning rate was 4°/min from 3° (2θ) to 60°. FTIR spec-
tra were recorded for analyzing the interaction PAC and
csMSN using an FT-IR spectrometer (Bruker IFS 55,
Switzerland) over 400 to 4000 cm−1 using the KBr pellet
technique.
In Vitro Drug Dissolution
Dissolution testing was performed using a USP dissol-
ution apparatus type II (RC-8D, Tianjin Guoming
Medical Equipment Co., Ltd.). The dissolution medium
was pH 7.4 phosphate buffer with 1% Tween 80. For
this, 10 mg PAC and PAC-csMSN powder containing an
equivalent of 10 mg PAC were respectively put in
1000 ml dissolution medium at a temperature of 37 ±
0.5 °C and the paddle speed was 100 rpm/min. Then,
5 ml samples of dissolution medium were withdrawn at
5, 10, 15, 20, 30, 45, and 60 min and passed through a
0.22 μm microporous membrane filter for HPLC ana-
lysis. The detection wavelength was 227 nm, and the
mobile phase was acetonitrile and water with a volume
ratio of 50:50 [17].
In Vivo Pharmacokinetic Study
Animals and Dosing
The animal experiment was approved by the Jinzhou
Medical University Laboratory Animal Ethics Committee.
Twelve rabbits (2.5 ± 0.5 kg) were randomly assigned to
two groups for evaluating the pharmacokinetics of PAC-
csMSN powder and PAC powder after pulmonary
administration. After fasting for 12 h, one group was given
a suspension of PAC-csMSN powder containing 2%
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hypromellose (equivalent to 10 mg PAC) while the other
group was given an aqueous suspension of PAC powder
(10 mg) containing 2% hypromellose by the trachea
cannula-instillation method [18, 19]. All rabbits had free
access to drinking water throughout the study. Blood sam-
ples (3.0 ml) were collected from the ear vein at 0.5, 1, 1.5,
2, 2.5, 3, 4, 5, 6, 8, 12, and 24 h and centrifuged at
5000 rpm for 10 min. The obtained plasma samples were
stored at −20 °C.
Six rabbits (2.5 ± 0.5 kg) were randomly assigned to
two groups for evaluating the inhalation safety of PAC-
csMSN powder and csMSN powder after pulmonary ad-
ministration. The csMSN group and PAC-csMSN group
received continuous administrations for 3 days, and then
the lung tissues were removed for pathological study.
Lung specimens were fixed with formalin and embedded
into paraffin then sectioned in a thin-slice cutting
machine. The obtained tissue sections were stained with
hematoxylin and eosin (H&E) and observed under a
fluorescent microscope.
Determination of PAC in Plasma
PAC plasma concentrations were determined by HPLC
(L-2400, HITACHI, Japan) with a UV–vis detector. A
Welch C18 column (4.6 mm × 200 mm, 5 μm) was used
for analysis, and the mobile phase was a mixture of
acetonitrile and water (50:50, v/v). Detection was carried
out at a flow rate of 1 ml/min. Butylparaben was se-
lected as the internal standard, and UV detection was
performed at 227 nm [17]. Plasma samples (1 ml) were
transferred to 10-ml centrifuge tubes, and then 20 μl in-
ternal standard solution (50 μg/ml) was added. After
vortex mixing for 5 min, 5 ml methyl tert-butyl ether
was added followed by vortexing for a further 10 min.
After centrifuging at 10,000 rpm for 10 min, the organic
layer of each sample was transferred to another centri-
fuge tube, then evaporated at 40 °C using a centrifugal
drying machine (LNG-T120, Hualida, China). The resi-
due was dissolved in 50 μl mobile phase and centrifuged
at 10,000 rpm for 10 min. Finally, 20 μl supernatant was
subjected to HPLC analysis. All the pharmacokinetic
data on PAC were analyzed using DAS 2.0 software.
In Vitro Cytotoxicity Assay
The MTT assay examines the mitochondrial activity of
the cells which is reflected by blue formazan crystals.
A549 cells were seeded in 96-well plates at a density of
1 × 105 cells per well. The cytotoxicity of csMSN, PAC,
and PAC-csMSN was measured in cell monolayers by
exposure to csMSN, PAC, and PAC-csMSN suspension
at different concentrations for 72 h. The concentrations
of csMSN were 12.5, 25, 50, 125, 250, and 500 μg/ml.
According to the conversion of drug loading, the series
concentration of PAC-csMSN were equivalent to 10, 20,
40, 80, 160, and 320 μg/ml of PAC concentration. MTT
solution (20 μl/well) was added and incubated for 4 h.
Next, DMSO (200 μl) was added and the cytotoxicity
was determined by a Plate Reader (DNM-9606) at
492 nm (Tecan, Germany) [20].
The Flow Cytometry Assays
A549 cells were seeded in 6-well plates, and a density
was 1 × 105 cells per well. After cells had attached and
proliferated for 24 h, the culture medium was removed
and the adherent cells were washed with PBS. A549 cells
treated with serum-free 1640 culture medium were used
as a control. PAC (5, 10 ng/ml) and PAC-csMSN
(equivalent to 5 and 10 ng/ml of PAC concentration)
were added and incubated for 48 h. Treated A549 cells
were washed three times with PBS, then harvested by
trypsinization. The cells collected by centrifugation were
suspended in 500 μl binding buffer. Next, 5 μl Annexin
V-FITC and 5 μl PI (Nanjing Jiancheng Biological
Science and Technology Co., Ltd., China) were added
and incubated for 15 min at room temperature in the
dark [8]. The apoptosis of A549 cells was determined by
flow cytometry (Becton Dickinson, CA).
Preparation of FITC-csMSN and LSCM Observation in Uptake
Experiments
The surface of csMSN with an amino group (csAMSN)
was achieved by an amination reaction [21]. csMSN
(500 mg) was heated in an oven at 100 °C for 30 min in
order to remove water. Then, anhydrous alcohol (50 ml)
was added in a three-necked flask, and APTES (2 ml)
was dripped slowly into the suspension under stirring.
The reaction was carried out at 77 °C for 10 h in a water
bath, and the whole process was under a nitrogen at-
mosphere. The csAMSN was obtained by centrifugation
and washed three times with ethanol and dried at 50 °C.
Next, csAMSN (100 mg) was added to 1 ml FITC alco-
hol solution (1 mg/ml) and allowed to stand for 4 h
under stirring. FITC-labeled csAMSN (FITC-csMSN)
was obtained by centrifugation and dried in a vacuum.
A549 cells were seeded in 6-well plates, and a density
was 5 × 104 cells per well. After cells had attached and
proliferated for 48 h, the culture medium was removed
and the adherent cells were washed with PBS. FITC-
csMSN (50 μg/ml) was added and incubated for 0.5, 1,
and 2 h. After washing three times with PBS, the A549
cells were fixed in 4% formaldehyde PBS solution for
10 min. After removing the medium and washing three
times with PBS, the A549 cells were then incubated in
0.1% of Triton X-100 PBS solution containing 10%
bovine serum albumin for 30 min. Then, the cells were
stained with 1 μg/ml Hoechst 33342 PBS solution for
20 min, followed by Rhodamine-phalloidin PBS solution
for 20 min and then washed twice with PBS [22]. Finally,
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the cell uptake of FITC-csMSN was examined by laser
scanning confocal microscopy (LSCM; Leica, Germany).
Transmission Electron Microscopy (TEM) Study
A549 cells were seeded in 6-well plates and a density of
5 × 104 cells per well. After the cells had attached and
proliferated for 24 h, the culture medium was removed
and the adherent cells were washed with PBS. csMSN
(50 μg/ml) dispersed in serum-free 1640 culture medium
was added to the 6-well plates and incubated for 4 h.
After removing the medium, the cells were washed three
times with PBS in order to detach the free csMSN. The
collected cells from the 6-well plates were fixed in 2%
glutaraldehyde solution for 12 h at 4 °C and then em-
bedded in 2% agarose gel. Next, A549 cells were fixed in
4% of osmium tetroxide solution. After dehydration, the
cells were embedded in epoxy resin, and the embedding
resin block was polymerized at 60 °C for 24 h [23].
Finally, ultrathin sections (50–70 nm) were obtained




The morphology and structure of csMSN were examined
by SEM and TEM. As seen in Fig. 1a, the SEM images
clearly had a spherical appearance with an average par-
ticle size of 200 nm. The TEM image in Fig. 1b showed
that csMSN had a core-shell structure. The core was
solid and the shell had a mesoporous structure which
made it suitable as a carrier for absorbing poorly water-
soluble drugs. Its characteristics were consistent with
those in the literature [15]. The specific surface area,
pore size, and volume of csMSN were 585 m2/g,
0.33 ml/g, and 5.79 nm, respectively. The space-limiting
effect of the nanometer pores could restrict the size of
drug particles and prevented their agglomeration. All of
these factors were responsible for improving the drug
dissolution. The drug loading of csMSN increased along
with the PAC concentration. When the PAC concentration
was more than 300 mg/ml, csMSN had the maximum drug
loading (45.7 ± 1.31%).
Solid State Characterization
XRD results revealed that the PAC adsorbed into the
mesoporous structure of the shell was in an amorphous
form. As seen in Fig 2a, PAC-csMSN did not exhibit any
characteristic crystalline reflection of PAC at 12.6° in
comparison with PAC powder and the corresponding
physical mixtures. The DSC results were also fully con-
firmed by the XRD conclusions. As shown in Fig 2b, the
phase inversion temperature of PAC powder was at
Fig 1 The SEM image of the csMSN (a) and the TEM image of the csMSN (b)
Fig 2 PAC state characterization (a XRD patterns, b DSC patterns)
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223 °C. However, the absence of a PAC melting peak in
PAC-csMSN further confirmed that the PAC absorbed
into csMSN existed in an amorphous state compared
with that of the corresponding physical mixtures [24].
In Vitro Drug Dissolution
The effect of the mesoporous structure of csMSN on the
PAC dissolution was shown in Fig. 3. The cumulative
dissolution of PAC at 1 h was 27.83 ± 3.724% for PAC
powder while the corresponding amount was 85.68 ±
2.585% for PAC-csMSN. Clearly, the dissolution rate
was significantly improved due to the high dispersion of
the shell mesoporous structure of csMSN. The reason
was that PAC was present in an amorphous form
because of the spatial confinement effect of the mesopo-
rous structure [25].
In Vivo Experiment
PAC concentrations were determined in rabbit plasma at
different times. The concentration–time profiles were
shown in Fig. 4, and the pharmacokinetic parameters
were listed in Table 1. The Cmax, Tmax, and AUC of
PAC-csMSN powder were 61.32 ± 13.82, 4.316 ± 1.214,
and 358.4 ± 32.56 compared with 44.76 ± 8.061, 3.632 ±
0.875, and 133.8 ± 21.45 for PAC powder, which indi-
cated that PAC-csMSN powder had a faster and greater
absorption by the alveoli. This result is directly related
to the amorphous nature of PAC in PAC-csMSN pow-
der. The amorphous PAC, as demonstrated during the
in vitro release test, provided a higher concentration of
dissolved PAC in the surrounding lung fluid compared
with the crystalline PAC powder and was immediately
absorbed due to its good cell membrane permeability.
Based on the Noyes–Whitney equation, the higher
absorption of amorphous PAC (a BSC II class drug) was
closely correlated with the faster in vivo dissolution.
Pathology Study
The pathology study was used to analyze any changes in
lung tissue after administration. As seen in Fig. 5a, the
cells in the tissue section of the normal lung specimen
of the csMSN group were uniformly spongy and the
lung tissue showed no signs of edema and congestion.
No macrophages were found in the alveoli. By contrast,
the PAC-csMSN group in Fig. 5b also showed no inflam-
mation, which indicated that the PAC-csMSN nanodrug
delivery system was biologically safe for continuous
administration in the short term.
In Vitro Cytotoxicity Assay and Apoptosis Analysis
The csMSN were incubated with A549 cells for 72 h at
different concentrations (from 12.5 to 500 μg/ml). As
seen in Fig. 6a, the viability of the A549 cells was above
90% at a high concentration of 500 μg/ml. These results
showed that csMSN is nontoxic, which is consistent with
a previous literature report [26]. For the PAC and PAC-
csMSN groups, the samples were incubated with A549
cells for 72 h at different concentrations (ranging from
10 to 320 μg/ml). As seen in Fig. 6b, the viability of
A549 cells in the PAC-csMSN groups decreased sig-
nificantly compared with the PAC groups. The cell
inhibition rate was increased from 35.21% ± 2.652 at
10 ng/ml PAC to 76.43% ± 4.634 at 320 ng/ml PAC
Fig 3 In vitro drug cumulative dissolution percentage patterns of
PAC-csMSN powder and PAC powder (n = 3)
Fig 4 Plasma concentration versus time profiles after pulmonary
administration of PAC-csMSN powder and PAC powder in rabbits (n= 6)
Table 1 The pharmacokinetic parameters of PAC and PAC-csMSN
Formulation Cmax
(μg/ml)
Tmax (h) t1/2 (h) AUC (μg/ml*h)
PAC 44.76 ± 8.061 3.632 ± 0.875 4.271 ± 1.174 133.8 ± 21.45
PAC-csMSN 61.32 ± 13.82 4.316 ± 1.214 5.456 ± 2.057 358.4 ± 32.56
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for PAC-csMSN. These results showed that PAC-
csMSN had distinct anti-proliferative effects which
were concentration-dependent. The in vitro antitu-
mor effects of PAC-csMSN can be quantitatively
evaluated by IC50, which is defined as the drug con-
centration at which 50% of the cells have been killed
in a designated time period. The IC50 values of
PAC-csMSN groups and PAC groups were 30.74 ±
5.175 and 125.9 ± 3.762 ng/ml, respectively. These
results indicated that the IC50 values of the PAC-
csMSN groups were markedly lower (p < 0.05) than
those of the PAC groups and the IC50 values of the
PAC groups was even four times than that of PAC-
csMSN groups. The reason for this is that the
mesoporous structure of csMSN can improve the
solubility of PAC which allows the cells to be
exposed to high concentrations of drug which in-
hibits cell proliferation.
Fig 5 Lung sections after pulmonary administration of csMSN powder (a) and PAC-csMSN powder (b) in rabbits
Fig 6 Cytotoxicity assay of csMSN (a) and PAC-csMSN (b); apoptosis analysis of PAC-csMSN and PAC (c)
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The analysis of apoptosis further confirmed the
cytotoxicity results. As seen in Fig 6c, PAC-csMSN
(34.3%) clearly promoted apoptosis compared with
pure PAC (11.0%) at the same concentration (5 ng/
ml) and the effect was constantly enhanced by an in-
crease in PAC concentration. The early apoptosis rate
of PAC-csMSN and pure PAC (10 ng/ml) were 19.6
and 40.7%, respectively. These results suggested that
PAC-csMSN plays an important good role in promot-
ing apoptosis.
Cell Uptake Study
The transport of FITC-csMSN was examined by
LSCM. A549 cells were incubated with 50 μg/ml
FITC-csMSN in serum-free 1640 medium for different
times. The results obtained indicated that the cellular
uptake was time-dependent. As shown in Fig 7a–c,
FITC-csMSN with 200 nm were taken up into A549
cells after 0.5 h incubation at 37 °C and formed green
fluorescent aggregates in the cytoplasm after 2 h.
However, as time continued, FITC-csMSN did not
penetrate into the nucleus despite the amount of up-
take gradually increasing. The intracellular distribu-
tion of csMSN in the A549 cells was also further
examined by TEM, which further supported the ob-
served LSCM images. The possible mechanisms for
the cellular uptake of csMSN involve nonspecific
diffusion, phagocytosis, and endocytosis [27, 28]. As
shown in Fig 7d, e, csMSN was taken up into A549
cells by endocytosis and accumulated in the vesicular
or cytosolic compartment inside the A549 cells. The
TEM images of ultrathin sections provide visual
evidence on the cellular uptake of csMSN [29]. The
results fully confirmed that the csMSN increased the
absorption of drug with the aid of a nanoeffect and
then to promote cell apoptosis.
Conclusions
csMSN increased the dissolution of PAC and improved
PAC absorption in the lungs. PAC in PAC-csMSN was
in an amorphous state in the mesoporous structure.
PAC-csMSN could be taken up into the cytoplasm and
promoted the apoptosis of A549 cells. All these findings
demonstrate that csMSN, with good biocompatibility
and biosafety, has the potential to be used as a carrier
for pulmonary inhalation of PAC for the treatment of
lung cancer.
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